MALT1 and psoriasis: Thirdly, from the results of subgroup analyses, blood MALT1 seemed to have a stronger ability to distinguish psoriasis patients with current initiating systemic biologic therapy who achieved PASI 75 and 90 at M6 from those who did not achieve that.